Cite
HARVARD Citation
Kantarjian, H. et al. (2022). Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia. American journal of hematology. 97 (11), pp. 1419-1426. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Kantarjian, H. et al. (2022). Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia. American journal of hematology. 97 (11), pp. 1419-1426. [Online].